Cargando…
Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer
Enzalutamide, an androgen receptor inhibitor, has been clinically approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) in the United States. However, patients only benefit from enzalutamide for a short period of time as resistance may develop. Therefore, it is vital t...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400968/ https://www.ncbi.nlm.nih.gov/pubmed/32782617 http://dx.doi.org/10.3892/ol.2020.11823 |